Is Serum or Plasma More Appropriate for Intersubject Comparisons in Metabolomic Studies? An Assessment in Patients with Small-Cell Lung Cancer

详细信息    查看全文

• 作者：David C. Wedge ; J. William Allwood ; Warwick Dunn ; Andrew A. Vaughan ; Kathryn Simpson ; Marie Brown ; Lynsey Priest ; Fiona H. Blackhall ; Anthony D. Whetton ; Caroline Dive ; Royston Goodacre
• 刊名：Analytical Chemistry
• 出版年：2011
• 出版时间：September 1, 2011
• 年：2011
• 卷：83
• 期：17
• 页码：6689-6697
• 全文大小：870K
• 年卷期：v.83,no.17(September 1, 2011)
• ISSN：1520-6882

文摘

In clinical analyses, the most appropriate biofluid should be analyzed for optimal assay performance. For biological fluids, the most readily accessible is blood, and metabolomic analyses can be performed either on plasma or serum. To determine the optimal agent for analysis, metabolic profiles of matched human serum and plasma were assessed by gas chromatography/time-of-flight mass spectrometry and ultrahigh-performance liquid chromatography mass spectrometry (in positive and negative electrospray ionization modes). Comparison of the two metabolomes, in terms of reproducibility, discriminative ability and coverage, indicated that they offered similar analytical opportunities. An analysis of the variation between 29 small-cell lung cancer (SCLC) patients revealed that the differences between individuals are markedly similar for the two biofluids. However, significant differences between the levels of some specific metabolites were identified, as were differences in the intersubject variability of some metabolite levels. Glycerophosphocholines, erythritol, creatinine, hexadecanoic acid, and glutamine in plasma, but not in serum, were shown to correlate with life expectancy for SCLC patients, indicating the utility of metabolomic analyses in clinical prognosis and the particular utility of plasma in relation to the clinical management of SCLC.